Dorian Therapeutics names new director
10 February 2021 -

Dorian Therapeutics, a biotechnology company, announced on Tuesday that it has named Jeff George as its new director.

George has more than 20 years of global healthcare, corporate, and investment leadership experience across North America, Europe, and emerging markets. Presently, he is serving as managing partner of Maytal Capital and an operating partner at Revival Healthcare Capital. He held the position of global division head and CEO of two divisions of Novartis, Sandoz and Alcon. He is the Directors of Amneal Pharmaceuticals and Wishbone Medical, and earlier served on the boards of AdvaMed and Roam Analytics.

Maddalena Adorno, PhD, Dorian Therapeutics cofounder and CEO, said, 'Dorian Therapeutics is rapidly scaling our R&D programs and organisation as we look to partner with leading pharmaceutical and healthcare organisations to make our therapeutics widely accessible. Jeff George is an excellent addition to our board and brings a wealth of leadership, strategic, and operational experience, which will help us to accelerate our efforts to create value for patients, shareholders, and other stakeholders.'